Nerve growth factor is preformed in and activates human peripheral blood eosinophils☆,☆☆,★,★★
Section snippets
Subjects
Thirteen subjects (mean age, 18 years; range, 9 to 26 years) were studied. All subjects had mild blood eosinophilia (range, 4% to 10%). The majority of subjects had signs and symptoms of allergic disease: 5 patients had vernal keratoconjunctivitis, 3 patients had allergic rhinitis, 2 patients had allergic conjunctivitis, and 1 patient had mild bronchial asthma. Two subjects were asymptomatic, and the cause for their eosinophilia could not be attributed to any specific morbid condition by common
Effect of NGF on EPO release
Twenty-minute incubation of eosinophils with various concentrations of NGF caused a dose-dependent EPO release compared with incubation of eosinophils in medium alone (Fig 1).
DISCUSSION
Attention and interest have recently focused on the role NGF plays in allergic and immunologic diseases.10, 11, 12 Several studies indicate that NGF can affect various immune and inflammatory cells through specific receptors present on their membranes.7, 8, 9 On the other hand, NGF is also produced and stored by immune cells such as mast cells and CD4+ cells.8, 9, 10, 13
In this report we show that NGF can induce circulating human eosinophils to release EPO, an important proinflammatory
Acknowledgements
We thank Mrs Dalia Pickholz for skillful technical assistance.
References (35)
- et al.
Mast cells increase in tissues of neonatal rats injected with nerve growth factor
Brain Res
(1977) - et al.
Mediator release from mast cells by nerve growth factor: neurotrophin specificity and receptor mediation
J Biol Chem
(1993) - et al.
Expression of functional TrK A receptor Tyrosine Kinase in the HMC-1 human mast cell line and in human mast cells
Blood
(1997) - et al.
Intracellular localization of interleukin-6 in eosinophils from atopic asthmatic and effects of interferon-γ
Blood
(1998) - et al.
A kinetic assay for eosinophil peroxidase activity in eosinophils and eosinophil conditioned media
J Immunol Methods
(1991) - et al.
Single step method of RNA isolation by acid guanidium thiocyanate phenol-chloroform extraction
Anal Biochem
(1987) - et al.
Expression of neurotrophic genes in human fibroblasts: differential regulation of the brain-derived neurotrophic factor gene
Int J Dev Neurosci
(1994) - et al.
Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophils on immunoglobulin-dependent activation
J Allergy Clin Immunol
(1991) - et al.
Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1α
Blood
(1988) - et al.
Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF
Blood
(1989)
Effects of T-helper 2-type cytokines interleukin 3 (IL-3), IL-4, IL-5 and IL-6 on the survival of cultured human mast cells
Blood
Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the Trk proto-oncogene receptor
Blood
The nerve growth factor (NGF).
Neurotrophic factors
Science
The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases
Allergy
The role of mast cell degranulation products in mast cell hyperplasia, I: mechanism of action of nerve growth factor
J Immunol
Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells
J Exp Med
Cited by (193)
The multifaceted aspects of ocular allergies: Phenotypes and endotypes
2022, Ocular SurfaceEosinophils, Mast Cells and Basophils
2022, Comprehensive PharmacologyAsthma and autoimmunity
2022, Translational Autoimmunity: Autoimmune Disease Associated with Different Clinical FeaturesRole of innate immunity in chemotherapy-induced peripheral neuropathy
2021, Neuroscience LettersSynergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases
2019, Cytokine and Growth Factor ReviewsMast cell and eosinophil surface receptors as targets for anti-allergic therapy
2017, Pharmacology and Therapeutics
- ☆
From athe Department of Ophthalmology, Hadassah University Hospital, and bthe Department of Pharmacology, School of Pharmacy, Hebrew University–Hadassah Medical School, Jerusalem; cInstitute of Neurobiology, Consiglio Nazionale delle Ricerche (CNR); dthe Department of Ophthalmology, University Tor Vergata–G.B. Bietti Eye Foundation, and eInstitute of Experimental Medicine CNR, Rome; and fClinical Immunology and Allergology, Second University of Naples.
- ☆☆
Supported by a grant from The Joint Research Fund of The Hebrew University and Hadassah University Hospital, Jerusalem, Israel.
- ★
Reprint requests: Francesca Levi-Schaffer, PhD, Department of Pharmacology, School of Pharmacy, The Hebrew University–Hadassah Medical School, POB 12065, Jerusalem 91120, Israel.
- ★★
0091-6749/98 $5.00 + 0 1/1/91947